Incyte Corporation's (NASDAQ: INCY) Jakafi is the only approved treatment for myelofibrosis, and that's turned Jakafi into a billion-dollar blockbuster drug. The company's enviable market position could be coming to an end, though, because two competing drugs are making their way toward the FDA.Can Incyte maintain its dominance in this indication or will new drugs from Celgene (NASDAQ: CELG) and Geron Corp (NASDAQ: GERN) carve away at Jakafi's sales.Image source: Getty Images.A big need for new treatmentMyelofibrosis is a tough-to-treat bone marrow disease with a poor prognosis and limited treatment options. It leads to an enlarged spleen, fatigue, and pain. Over time, it can turn into life-threatening leukemia.The disease is characterized by decreased production of red blood cells in the bone marrow caused by scarring resulting from the overproliferation of abnormal cells. The only curative treatment is a bone marrow transplant; however, high mortality rates and complications make … [Read more...] about Incyte Could Have a Problem (or 2!) on Its Hands
Even though Apple (NASDAQ: AAPL) recorded record revenue and earnings per share (EPS) in the first quarter of 2018, questions remain about the company's long-term prospects.That's at least in part because the company has struggled to create a hit product since it released iPhone in 2007. Of course, that's a very high standard as Apple Watch and Apple TV would be considered successful products at most companies.Apple has created a very high bar for itself. That at least raises the question as to whether investors should buy shares in the company or whether its best days are behind it.Apple generally releases a new iPhone or at least a refresh in the fall. Image source: Apple.The numbers look goodOn a purely numerical basis, Apple has been killing it. The company posted Q1 2018 revenue of $88.3 billion, a 13% increase over the same period a year ago. Earnings per share (EPS) were up over 2017 as well climbing 16% to $3.89."We're thrilled to report the biggest quarter in Apple's history, … [Read more...] about Is Apple Inc. a Buy?